TipRanks identified the corporate insiders with the best-performing track records and found which health-care stocks they like right now. We differentiate between informative and

uninformative insider transactions in order to find the most compelling opportunities. Uninformative transactions indicate that an insider is buying/selling shares for reasons that do not

necessarily indicate confidence in the company, such as exercising share options. In contrast, informative transactions are deliberately made by insiders, often because they feel the stock

is undervalued. In this case, we looked at stocks that exhibit strong buy indicators based on informative transactions of top insiders who are company executives, board members or 10 percent

20. Shares in Corbus have exploded in the last year from just $1.8 to the current share price of $9 through Thursday. The company, which develops therapies for rare inflammatory diseases

such as cystic fibrosis, is currently testing its potentially groundbreaking drug Anabasum in four separate Phase 2 clinical trials. On Mar. 14 both Cantor Fitzgerald's Elemer Piros and

Noble Financial's Mark Jordan issued buy ratings on CRBP stock. Piros' price target for Corbus is $17, representing an 89 percent upside from Thursday's close. 2. La Jolla

Pharmaceutical (LJPC) Director Kevin Tang bought shares in La Jolla Pharmaceutical , worth $3.4 million on Mar. 6, bringing his total LJPC holding to $110 million. CEO George Tidmarsh also

bought shares in the stock on the same day worth $102,490. La Jolla develops therapies to improve outcomes in patients suffering from life-threatening diseases. Share prices soared over 50

percent at the end of February after the company announced positive Phase 3 trial data for its novel hypotension treatment. SunTrust analyst Yatin Suneja says the pipeline product, LJPC-501,

could represent a $500 million-plus opportunity. La Jolla has a strong buy analyst consensus rating on TipRanks with five buy ratings published in the last three months and an average

analyst price target of $56, representing 60 percent upside from Thursday's close. 3. Bruker (BRKR) Bruker is a manufacturer of scientific instruments for molecular and materials

research. On Mar. 20, CEO Frank Laukien added shares worth $100,000 to his $889 million BRKR holding, which is his third purchase of the company's shares in the last three months. The

stock has a moderate buy analyst consensus rating on TipRanks, with Jefferies analyst David Windley reiterating his buy rating on Mar. 20 with a $29 price target, representing 25 percent

upside from Thursday's close. Editor's note: TipRanks is a fintech company that ranks analysts and financial bloggers based on their picks' performance. This piece highlights

analysts with great track records who are not necessarily from the biggest firms. Dr. Yuval Cohen, Corbus CEO, featured on "Mad Money with Jim Cramer" on October 19, 2016. Ashlee

Espinal | CNBC TipRanks identified the corporate insiders with the best-performing track records and found which health-care stocks they like right now. We differentiate between informative

and uninformative insider transactions in order to find the most compelling opportunities. Uninformative transactions indicate that an insider is buying/selling shares for reasons that do

not necessarily indicate confidence in the company, such as exercising share options. In contrast, informative transactions are deliberately made by insiders, often because they feel the

stock is undervalued. In this case, we looked at stocks that exhibit strong buy indicators based on informative transactions of top insiders who are company executives, board members or 10

percent shareholders of publicly traded companies. Below are three health-care stocks highly ranked corporate insiders are buying.